Von Willebrand factor–Coagulation factor VIII complex (VWF–FVIII complex)

The Von Willebrand factor (VWF)–Coagulation factor VIII (FVIII) complex is a vital non-covalent assembly in plasma that regulates blood clotting and prevents excessive bleeding. VWF acts as a dedicated chaperone for FVIII, shielding it from premature proteolytic degradation and rapid clearance from the circulation, which maintains therapeutic levels of FVIII (PubMed: 28336630). In the absence of VWF, FVIII is highly unstable and is cleared within minutes; however, when bound to the D'D3 domains of VWF, its half-life is extended to approximately 15 hours (StatPearls: Von Willebrand Disease). This complex is the primary target for replacement therapies in patients with Hemophilia A and Von Willebrand disease, where plasma-derived or recombinant versions are administered to restore hemostasis. Modern bioengineering has also utilized the VWF chaperone domains to create long-acting FVIII fusion proteins, such as Efanesoctocog alfa, which overcome the half-life ceiling imposed by endogenous VWF (NEJM: 388:310-318). Overall, the complex is essential for both the transport of FVIII and the initiation of platelet-mediated clot formation at sites of vascular injury.

Other names

Factor VIII/von Willebrand factor complexVWF-FVIII complexAntihemophilic factor/von Willebrand factor complexFVIII/VWF complex

The complex functions by providing a stable carrier for Factor VIII in the bloodstream, preventing its rapid degradation by activated protein C and clearance by hepatic receptors such as LRP1. Upon vascular injury, thrombin cleaves Factor VIII, releasing it from the VWF chaperone to participate in the tenase complex of the coagulation cascade (Lenting et al., Blood 2017).